Analyst Ratings for Editas Medicine
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Editas Medicine (NASDAQ:EDIT) within the last quarter, with 2 bullish, 2 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for the company is $14.0, representing a 9.68% decrease from the previous average price target of $15.50.
October 18, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mixed analyst ratings and a lower average price target could impact Editas Medicine's stock.
Analyst ratings can significantly influence investor sentiment and stock performance. The mixed ratings for Editas Medicine, coupled with a lower average price target, could lead to uncertainty among investors and potentially negatively impact the stock's short-term performance.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100